Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s capacity for cellular growth and repair. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.

TypePublic
HQCambridge, US
Founded2003
Size (employees)121 (est)
Websiteacceleronpharma.com
Acceleron Pharma was founded in 2003 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

CFO
Steven Ertel

Steven Ertel

COO
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Show more

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street
Show all (1)
Report incorrect company information

Acceleron Pharma Financials and Metrics

Acceleron Pharma Revenue

Acceleron Pharma's revenue was reported to be $13.48 m in FY, 2017
USD

Revenue (Q2, 2018)

6.9m

Net income (Q2, 2018)

(55.2m)

EBIT (Q2, 2018)

(57.5m)

Market capitalization (15-Oct-2018)

2.2b

Closing stock price (15-Oct-2018)

48.7

Cash (30-Jun-2018)

79.6m
Acceleron Pharma's current market capitalization is $2.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

57.2m14.6m18.1m27.8m13.5m

Revenue growth, %

(74%)24%53%

General and administrative expense

25.3m33.7m

R&D expense

68.6m89.7m
Quarterly
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

3.3m5.7m4.2m18.2m3.2m3.0m3.7m3.1b3.2m6.9m

General and administrative expense

3.8m4.7m5.4m5.9m6.7m6.4m7.8m11.4b7.4m15.1m

R&D expense

11.8m14.2m13.3m16.2m16.1m17.1m21.7m21.6b23.4m49.4m

Operating expense total

15.5m18.8m18.8m22.2m22.9m23.5m29.6m33.0b30.9m64.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

113.2m176.5m27.8m21.0m100.2m

Accounts Receivable

11.5m

Inventories

2.2m2.5m2.5m3.9m

Current Assets

119.0m182.3m110.9m146.8m285.2m
Quarterly
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

214.1m43.4m63.7m37.0m31.0m33.2m30.7m69.7m79.6m

Current Assets

218.5m122.4m170.7m127.0m145.0m149.0m148.4m300.3m299.1m

PP&E

3.7m2.9m3.7m4.2m4.2m7.1m7.2m7.0m6.9m

Total Assets

223.0m158.4m289.6m274.2m262.9m229.1m208.5m370.0m351.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.9m)(51.3m)(63.9m)(57.0m)(108.5m)

Depreciation and Amortization

915.0k1.1m1.2m1.7m2.8m

Inventories

(823.0k)(255.0k)7.0k(1.4m)

Accounts Payable

(53.0k)(161.0k)151.0k644.0k(504.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(9.1m)(10.4m)(11.9m)5.1m(22.0m)(25.4m)(26.2m)(55.2m)

Depreciation and Amortization

904.0k1.9m

Accounts Payable

891.0k2.6m3.3m1.6m1.8m2.6m1.2m566.0k2.1m911.0k591.0k183.0k

Cash From Operating Activities

(23.4m)(45.6m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 2
Show all operating metrics
Report incorrect company information

Acceleron Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Acceleron Pharma News and Updates

Key Findings of the Growth/Differentiation Factor 8 Market | Acceleron Pharma, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company

HTF MI published a new industry research that focuses on Growth/Differentiation Factor 8 market and delivers in-depth market analysis and future prospects of Global Growth/Differentiation Factor 8 market. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Acceleron Pharma Blogs

Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City

– Live presentation and webcast to be held on November 16 th  at 9:00 a.m. EST – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 16, 2018-- Acceleron Pharma Inc.  (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare

Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of

Acceleron Reports Second Quarter 2018 Operating and Financial Results

– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension –

Eric Joseph, Ph.D.

Eric Joseph, Ph.D. Brian.Hoenig@n… Thu, 08/02/2018 - 15:24 Eric Joseph, Ph.D. JP Morgan

Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results.

Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society

- Mean total muscle volume increases of more than 12% seen in the tibialis anterior – - Company plans to initiate Part 2 of the CMT Phase 2 trial in the third quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical

Acceleron Pharma Company Life and Culture

Report incorrect company information